Eli Lilly (LLY) is acquiring Centessa Pharmaceuticals (CNTA) for up to $7.8B ($38/share + $9 CVR) to enter sleep medicine with a potential best-in-class OX2R agonist pipeline for narcolepsy. This is Lilly's fourth major acquisition in roughly 12 months.

Biogen (BIIB) is acquiring Apellis Pharmaceuticals (APLS) for $5.6B ($41/share + $4 CVR), a staggering 140% premium to Monday's close. The deal adds two approved drugs (Syfovre, Empaveli) with $689M in 2025 revenue and significantly accelerates Biogen's kidney disease buildout.

The Macro Signal: $13.4B in biopharma M&A was announced on a single Tuesday. The deal machine is aggressively accelerating.

Also: Novo Nordisk's Awiqli, the first once-weekly basal insulin, was approved last week and launches H2 2026. In case you missed it.

Orforglipron (April 10): Lilly's oral GLP-1 target action date is exactly 9 days out. This approval would cap off Lilly's third major catalyst in two weeks (Insilico AI deal on Sunday, Centessa acquisition on Tuesday, orforglipron decision April 10).

Novo Wegovy HD Launch (April): The high-dose injectable is rolling out now across 70,000+ U.S. pharmacies.

Centessa Pipeline Data: The lead OX2R agonist is in Phase 2 for narcolepsy type 1 and 2. The CVR structure ($9/share contingent strictly on FDA approvals) tells you Lilly sees a highly viable regulatory path.

Apellis Integration: Biogen expects Apellis to add mid-to-high teens revenue growth through at least 2028. The Syfovre CVR ($4/share based on sales milestones) aligns financial incentives heavily on geographic atrophy commercial uptake.

What Happened: Eli Lilly (LLY) announced a definitive agreement to acquire Centessa Pharmaceuticals (CNTA) for $38 per share in cash at closing, plus a contingent value right (CVR) of up to $9 per share tied to U.S. regulatory approvals. The total potential value is up to $7.8B (~$6.3B upfront equity value). The deal represents a 38% premium to Monday's closing price and a 40.5% premium to the 30-day VWAP.

The Asset: Centessa is developing a pipeline of orexin-2 receptor (OX2R) agonists for narcolepsy and excessive daytime sleepiness—conditions driven by the loss of orexin-producing neurons in the brain. The lead candidate is in Phase 2, with analysts projecting multi-billion-dollar blockbuster potential. The OX2R agonist approach targets the root cause of narcolepsy rather than merely managing symptoms (which is what current stimulants do).

Executive Impact: This is Lilly's fourth major acquisition in approximately 12 months and the company's most significant push into neuroscience. Adding a potentially first-in-class narcolepsy franchise actively diversifies the revenue base beyond GLP-1 dependence. The CVR structure signals immense confidence: Lilly is willing to pay $47/share total if the drugs cross the FDA finish line. The close is expected in Q3 2026.

What Happened: Biogen (BIIB) announced a definitive agreement to acquire Apellis Pharmaceuticals (APLS) for $41 per share in cash plus a CVR of up to $4 per share tied to Syfovre sales milestones. The total upfront value is approximately $5.6B, representing a massive 140% premium to Apellis's Monday closing price.

The Assets: Apellis brings two approved complement-targeting therapies: Syfovre (pegcetacoplan for geographic atrophy) and Empaveli (pegcetacoplan for paroxysmal nocturnal hemoglobinuria). The two products generated $689M in combined 2025 revenue and are expected to grow at a mid-to-high teens CAGR through at least 2028.

Executive Impact: This is Biogen's largest acquisition in years. The institutional reality is that Biogen isn't just buying products; it is buying the Apellis nephrology commercial team that can support the upcoming launch of felzartamab, a CD38 antibody for kidney disease acquired through the $1.8B HI-Bio deal in 2024. The 140% premium tells you exactly how badly Biogen needed this deal to secure near-term growth. Close expected Q2 2026.

April 10: Eli Lilly orforglipron target action date (obesity NDA, CNPV)

April: Novo Nordisk Wegovy HD U.S. launch

H2 2026: Novo Nordisk Awiqli U.S. launch (first weekly basal insulin)

Q2 2026: Biogen/Apellis close expected

Q3 2026: Lilly/Centessa close expected

Late Q2 2026: Sarepta FDA meeting on SRP-1001 accelerated pathway

Mid-2026: Lilly retatrutide Phase 3 obesity readouts (TRIUMPH program)

Live directories include: AI Drug Discovery, CROs, CDMOs, Clinical Trial Technology, Biotech VC & Investors, Precision Medicine & Diagnostics, Gene & Cell Therapy, Biotech Recruiting, Lab Equipment & Tools, Digital Health & SaaS, Regulatory & Compliance, Legal & IP, Marketing Agencies, and Medical Devices.